Quoin posts Q2 net loss of $2.0M; cash $12.6M; expands Netherton trials internationally

Quoin Pharmaceuticals, Ltd.

Cash, cash equivalents and marketable securities of $12.6M as of June 30, 2024; expected to fund operations into late 2025.
Net loss for Q2 2024 was $2.0M ($2.1M in Q2 2023); six-month net loss $4.3M ($4.7M in prior year).
Signed research agreement with University College Cork for topical rapamycin formulations using dissolvable microneedle technology.
Expanded Netherton Syndrome clinical trials to international sites starting with Saudi Arabia and EU.
Announced plans to initiate clinical study in Peeling Skin Syndrome, first site and patient identified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.